Patented drugs for renal cancer

According to experts, the incidence of renal cancer in China is characterized by increasing with age, and males are higher than females. Although the diagnostic rate of renal cell carcinoma is high, 25%-30% of the patients who can be initially diagnosed are patients with advanced renal cell carcinoma, and about 30% of the patients who receive radical nephrectomy will progress. The 5-year survival rate of patients with progressive renal cell carcinoma is greater than 10%. Because patients with advanced renal cell carcinoma are insensitive to chemotherapy and radiotherapy, targeted drugs have become the standard treatment for advanced renal cell carcinoma.

In the field of treatment of renal cell carcinoma in China, although targeted therapy has made progress, patients with advanced renal cell carcinoma who have progressed after first-line treatment still need more treatment options, so that doctors can choose the best treatment for these patients. Inlida is the first targeted drug approved by the United States for patients with advanced renal cell carcinoma who failed in previous treatment. As a new generation of targeted drugs, Yinglida should be more effective, which can significantly prolong the progression-free survival by 86% compared with previous targeted drugs. I usually pay more attention to this information, so I suggest you go to the hospital to consult a doctor for details.